Trial of BMS-986012 in Combination With Platinum and Etoposide

• Status: Active, not recruiting
• Trial end date: 2021-07-26
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Carboplatin; Cisplatin; Etoposide; Etoposide phosphate

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Male and Females 18 years of age or older

• Pulmonary SCLC documented by histology or cytology

• Extensive disease (Stage IV) SCLC

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria:

• Prior systemic therapy for lung cancer

• Symptomatic brain metastases

• Grade 2 peripheral neuropathy

• Active or chronic infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV

• Other active malignancies or prior malignancy within 2 years

Other protocol defined inclusion/exclusion criteria could apply